Keros Therapeutics Inc. (KROS) News
Filter KROS News Items
KROS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest KROS News From Around the Web
Below are the latest news stories about KEROS THERAPEUTICS INC that investors may wish to consider to help them evaluate KROS as an investment opportunity.
Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should KnowKeros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and ExpositionKeros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET.LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from |
Wall Street Analysts Think Keros Therapeutics, Inc. (KROS) Could Surge 95%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 94.9% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Keros Therapeutics to Present at Upcoming Healthcare ConferencesLEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in fireside chat presentations at the Piper Sandler 34 |
Wall Street Analysts Believe Keros Therapeutics, Inc. (KROS) Could Rally 96%: Here's is How to TradeThe mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 96.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Analysts Are Bullish on These Healthcare Stocks: Keros Therapeutics (KROS), Corcept Therapeutics (CORT)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keros Therapeutics (KROS – Research Report), Corcept Therapeutics (CORT – Research Report) and Alphatec Holdings (ATEC – Research Report) with bullish sentiments. Keros Therapeutics (KROS) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics today and set a price target of $100.00. The company's shares closed last Friday at $48.64. According to TipRanks. |
Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific SessionsLEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced results from a preclinical study of a research form of KER-012 ("RKER-012") on cardiac and pulmonary pathology in an established rat model of pulm |
Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that five abstracts will be presented from the KER-050 and KER-047 hematology programs at the 64th American Society of Hematology (“ASH”) Annual M |
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial ResultsLEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended September 30, 2022. “Keros continued to build upon the posi |
Shareholders have faith in loss-making Keros Therapeutics (NASDAQ:KROS) as stock climbs 10% in past week, taking one-year gain to 13%These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can... |